Concepedia

Maria Verdugo

MV

Statistics

Publications

26

Citations

4.7K

H-Index

21

Active since

2001

Affiliations

AbbVie (United States)(Current)

The University of Texas MD Anderson Cancer Center

The Royal Melbourne Hospital

Peter MacCallum Cancer Centre

Emory University

Maria Verdugo is an author at AbbVie (United States) specializing in medicine, hematologic malignancy therapy, and immunotherapy.

Publications per year

2001–2019

26

Publications

26

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig et al. · The Lancet Oncology · 2016 · 796 citations · Full text

Medicine, Hematology, Immunology +7

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 751 citations

Medicine, Hematology, Pharmacokinetics +15

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto et al. · Blood · 2017 · 527 citations · Full text

Medicine, Hematology, Immunology +11

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jeffrey A. Jones, Anthony R. Mato, William G. Wierda et al. · The Lancet Oncology · 2017 · 378 citations · Full text

Life Sciences, Hematology, Immunology +12

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

John F. Seymour, Shuo Ma, Danielle M. Brander et al. · The Lancet Oncology · 2017 · 327 citations

Life Sciences, Hematology, Immunology +11

1–5 of 26